Cardiology

A Q&A with Dr. Bonaca highlights new data on rivaroxaban for PAD and the late-breaking science at AHA 2022.

Data from a pair of presentations at AHA 2022 Scientific Sessions provide clinicians with insight into the effects of surgical vs endovascular procedures for improving prognosis and reducing amputation in patients with peripheral artery disease.

In this episode of Don't Miss a Beat, hosts Muthiah Vaduganathan, MD, MPH, and Stephen Greene, MD, are bringing you insights from the AHA 2022 Scientific Sessions. In the episode, which was recorded on day 2 of the 3-day meeting, our hosts offer listeners perspective on the EMPA-KIDNEY and the TRANSFORM-HF trial, the latter of which Greene served on as an investigator.

The trial achieved its primary efficacy endpoint of terminating PSVT with self-administered etripamil, using symptom-based optional repeat dosing.

Results of the CTS-AMI study presented at AHA 22 suggests tongxiluo, which is an herbal medicine compound used in China, could reduce risk of cardiac events and mortality following a heart attack.

Patients with early VA-ECMO use saw comparable outcomes to those who initially received conservative therapy for hemodynamic stabilization.

Education and place of birth contribute the most to the racial and ethnic differences observed in mean CVH score.

The treatment reduced UACR by 37.1% and LDLc by 17.12 compared to placebo.

A single intravenous dose of NTLA-2001 significantly reduced abnormal levels of transthyretin in patients with ATTR amyloid cardiomyopathy, reports new data from AHA 2022.

Low sodium intake is considered less than 2.3 grams per day.

The late-breaking findings presented at AHA 2022 suggest the incidence of CV events was not lower among patients who received pemafibrate compared with those who received placebo.

Results of the TRANSFORM-HF trial presented at AHA 22 indicate there were no significant differences in rate of all-cause mortality or hospitalization with the use of torsemide compared with furosemide in people with heart failure.

In this column, Gregory Weiss, MD, provides perspective on a recent study providing evidence in support of metformin as a potential therapeutic option for treatment of atrial fibrillation.

National deaths from heart disease spiked in 2020 in the beginning of the COVID-19 pandemic, after an observed steady decline from 2010 to 2019.

Only 12% of people with CVD older than age 65 used wearable devices, despite estimates suggesting half of all people with CVD are older than age 65.

The 30-year analysis suggests a significantly higher risk associated with lead exposure and lower risk for particulate matter in the US than in the UK.

In a late-breaking abstract, investigators observed a 28% reduction in kidney disease progression or cardiovascular deaths compared to placebo.

Drs Erin Michos, Pam Taub, Robert Busch, Alison Bailey, and Jorge Plutzky, discuss use of ezetimibe and PCSK9 targeting agents for lipid lowering.

Drs Erin Michos, Pam Taub, Robert Busch, Alison Bailey, and Jorge Plutzky, discuss use of statins in managing hypercholesterolemia based on varying levels of risk.

The study shows vitamin D levels do not necessarily forecast the risk of cardiovascular disease in patients with chronic kidney disease.

Females generally have a lower risk of cardiovascular disease compared to males.

Data presented during ASN 2022 shows how heart failure impacts risk factors for renal outcomes of patients with chronic kidney disease.

An analysis of trends in cardiovascular disease-related mortality from the US CDC WONDER database provides new insight into the apparent increases in mortality from cardiovascular disease observed during 2020 relative to the decreases in rate seen from 2010-2019.

The Pompe disease community is anticipating the pivotal FDA decision for AT-GAA, a combination therapy for late-onset Pompe disease (LOPD) that has the potential to expand the armamentarium of physicians.

Alison Bailey, MD, FACC, reviews real-word data about LDL-C control and achievement of goals.

A panel of experts discuss the importance of achieving low-density lipoprotein cholesterol (LDL-C) in patients.

Welcome back to Crisis Point. A special episode focuses on the issue of insulin accessibility and affordability in the United States, with four experts in the diabetes arena weighing in on the topic.

An analysis of data from Nurses' Health Study II participants suggests long or irregular menstrual cycles were associated with an increased risk of incident cardiovascular disease later in life.

Patients with NAFLD were more likely to have comorbidities, including diabetes, hypertension, chronic respiratory disease, hypothyroidism, chronic kidney disease, sleep apnea, and hyperlipidemia.